09:16 AM EDT, 10/15/2024 (MT Newswires) -- Immuneering ( IMRX ) said Tuesday that its investigational drug IMM-1-104 has received orphan drug designation from the US Food and Drug Administration in the treatment of pancreatic cancer.

The company said a phase 2a clinical trial to evaluate IMM-1-104 combined with chemotherapy in patients with advanced solid tumors, including pancreatic cancer, is ongoing.

The company, which recently announced positive initial phase 2a results, said it expects to provide initial data from at least one additional arm of the phase 2a portion of its phase 1/2a trial before the end of the year.

Shares of Immuneering ( IMRX ) advanced 23% in premarket activity Tuesday.

Price: 2.4600, Change: +0.46, Percent Change: +23.00